Comparative efficacy and safety of seven stem cell therapies for ischemic stroke: an updated network meta-analysis.

NeuroscienceJul 21, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Weili Cao, Bo Zhu, Naibing Gu et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the efficacy and safety of seven stem cell therapies for ischemic stroke in 1,006 patients across 18 randomized controlled trials. Peripheral blood stem cells were found to be the most effective for neurological recovery, while mesenchymal stem cells significantly reduced mortality. The study highlights the varying benefits of different stem cell types.

Key findings

  • Peripheral blood stem cells ranked highest for neurological recovery.
  • Mesenchymal stem cells significantly reduced mortality.
  • Bone marrow-derived ALDHbr cells improved daily living outcomes.
  • Endothelial progenitor cells had the lowest serious adverse events.

Why it matters

Understanding the comparative efficacy and safety of different stem cell therapies can guide clinicians in selecting appropriate treatments for ischemic stroke, potentially improving patient outcomes and minimizing adverse effects.

Source

PubMed · PMID 42480897

Published in Neuroscience. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.